Cysteine cathepsins and their potential in clinical therapy and biomarker discovery

被引:46
|
作者
Fonovic, Marko [1 ,2 ]
Turk, Boris [1 ,2 ]
机构
[1] Jozef Stefan Inst, Dept Biochem Mol & Struct Biol, SI-1000 Ljubljana, Slovenia
[2] Ctr Excellence Integrated Approaches Chem & Biol, Ljubljana, Slovenia
关键词
Biomarker; Cancer; Cathepsin; Cysteine protease; Proteolysis; ACTIVITY-BASED PROBES; AORTIC-VALVE CALCIFICATION; INHIBITOR CYSTATIN-C; RHEUMATOID-ARTHRITIS; CANCER PROGRESSION; PROGNOSTIC MARKER; BONE-RESORPTION; SYNOVIAL-FLUIDS; S EXPRESSION; HISTONE H3;
D O I
10.1002/prca.201300085
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Since their discovery, cysteine cathepsins were generally considered to be involved mainly in the nonspecific bulk protein degradation that takes place within the lysosomes. However, it has become clear that their proteolytical activity can also influence various specific pathological processes such as cancer, arthritis, and atherosclerosis. Furthermore, their localization was found not to be limited strictly to the lysosomes. In the light of those findings, it is not surprising that cysteine cathepsins are currently considered as highly relevant clinical targets. Moreover, recent development of proteomic-based methods for identification of novel physiological substrates of proteases provides a major opportunity also in the field of cysteine cathepsins. In this review, we will therefore present cysteine cathepsin roles in disease progression and discuss their potential relevance as prognostic and diagnostic biomarkers.
引用
收藏
页码:416 / 426
页数:11
相关论文
共 50 条
  • [41] Synergistic approaches to clinical oncology biomarker discovery
    Belkowski, SM
    Polkovitch, D
    D'Andrea, MR
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 1047 - 1051
  • [42] Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery
    Kamada, Haruhiko
    Fugmann, Tim
    Neri, Dario
    Roesli, Christoph
    PROTEOMICS, 2009, 9 (03) : 783 - 787
  • [43] Clinical and biological data integration for biomarker discovery
    Sorani, Marco D.
    Ortmann, Ward A.
    Bierwagen, Erik P.
    Behrens, Timothy W.
    DRUG DISCOVERY TODAY, 2010, 15 (17-18) : 741 - 748
  • [44] Cysteine protease cathepsins in atherosclerosis and abdominal aortic aneurysm
    Sjöberg S.
    Shi G.-P.
    Clinical Reviews in Bone and Mineral Metabolism, 2011, 9 (2): : 138 - 147
  • [45] Cysteine cathepsins: A long and winding road towards clinics
    Biasizzo, Monika
    Javors, Urban
    Vidak, Eva
    Zaric, Miki
    Turk, Boris
    MOLECULAR ASPECTS OF MEDICINE, 2022, 88
  • [46] Fluorescent nitrile-based inhibitors of cysteine cathepsins
    Frizler, Maxim
    Mertens, Matthias D.
    Guetschow, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (24) : 7715 - 7718
  • [47] Degradomics in Biomarker Discovery
    Grozdanic, Marija
    Vidmar, Robert
    Vizovisek, Matej
    Fonovic, Marko
    PROTEOMICS CLINICAL APPLICATIONS, 2019, 13 (06)
  • [48] Cytokines regulate cysteine cathepsins during TLR responses
    Creasy, Blaine M.
    McCoy, Kathleen L.
    CELLULAR IMMUNOLOGY, 2011, 267 (01) : 56 - 66
  • [49] Cysteine Cathepsins: Structure, Physiological Functions, and the Role in Carcinogenesis
    Gureeva, T. A.
    Timoshenko, O. S.
    Kugaevskaya, E. V.
    Solovyova, N. I.
    BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY, 2022, 16 (02) : 91 - 103
  • [50] The Role of Cysteine Cathepsins in Cancer Progression and Drug Resistance
    Rudzinska, Magdalena
    Parodi, Alessandro
    Soond, Surinder M.
    Vinarov, Andrey Z.
    Korolev, Dmitry O.
    Morozov, Andrey O.
    Daglioglu, Cenk
    Tutar, Yusuf
    Zamyatnin, Andrey A., Jr.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)